Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, anti-viral, laxatives, and cold and cough therapeutic areas. Its product portfolio includes plain, enteric-coated, and film coated tablets; soft gelatin and hard capsules; oral liquids; and ointments, as well as creams and liquids. The company provides its products to supermarkets, high street retailers, pharmacy chains, and wholesalers. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.
Metrics to compare | MARK | Peers Peers - average of corresponding metrics from companies closely matching MARK: MOREPENLAB, KOPRAN, BLUEJET, CIPLA, GRANULES | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMARKPeersSector |
---|---|---|---|---|
P/E Ratio | 25.1x | 30.4x | −0.5x | |
PEG Ratio | 1.17 | 0.22 | 0.00 | |
Price/Book | 3.9x | 3.5x | 2.6x | |
Price / LTM Sales | 3.6x | 3.9x | 3.3x | |
Upside (Analyst Target) | 49.5% | 15.2% | 43.3% | |
Fair Value Upside | Unlock | 1.8% | 6.9% | Unlock |